Psychedelic experiences, particularly those induced by substances such as DMT, have long captivated human imagination and shamanic traditions due to their vivid sensory phenomena, including kaleidoscopic visuals, entity encounters, and disruptions of normal spatiotemporal perception. Despite their richness, these states have eluded quantitative scientific characterization. The joint effort between Noonautics, helmed by neurobiologist Dr. Andrew Gallimore, and the Trace Institute, led by cognitive scientist Professor Emeritus Donald Hoffman, aims to transcend anecdotal and qualitative accounts by applying mathematical models to the subjective reports and experimental data gathered under controlled conditions.

Central to this study is the DMTx protocol developed by Noonautics, a pioneering method that extends the duration of the traditionally brief DMT experience from mere minutes to several hours. This pharmacokinetic innovation enables trained scientists and selected experts—formally termed ‘observers’—to enter and navigate the DMT state with enhanced temporal resolution for precise observation and experimental manipulation. This extended access to the psychedelic realm lays the groundwork for systematic data acquisition that is critical for meaningful theoretical analysis.

On the theoretical front, Professor Hoffman and his team at the Trace Institute bring their expertise in conscious realism and trace logic—mathematical frameworks that conceive consciousness not as a mere by-product of neural processes but as the fundamental basis of reality. Their approach reframes perception as an interface shaped by evolutionary pressures rather than a veridical window to the physical world. Integrating this framework with empirical findings from the DMTx experiments, they aim to produce a quantitative model that can interpret and predict the nuanced phenomenology of the psychedelic state.

This interdisciplinary synthesis promises transformative implications. By providing a precise mathematical characterization of how psychoactive substances like DMT perturb the structure and function of spacetime as experienced by conscious agents, the research could redefine our understanding of both mind and reality. According to Hoffman, the project will “provide a new framework for exploring the effects of psychoactive substances such as DMT on the structure and function of spacetime,” highlighting the profound ontological questions at stake.

Equally, Gallimore sees the collaboration as establishing a foundational theory for altered states of consciousness, enabling empirically testable hypotheses. This experimental-theoretical feedback loop represents a novel paradigm in psychedelic science, moving away from purely phenomenological or neurochemical perspectives toward a rigorous integration of mathematical logic, pharmacokinetics, and first-person experiential data.

The broader vision articulated by the two investigators envisions the emergence of a ‘mathematics of altered states,’ which could ultimately facilitate the engineering of perceptual interfaces to expand human cognition and consciousness. Such advances might unlock new modalities of human experience and understanding, with profound implications for psychology, philosophy, and potentially even quantum physics.

Public engagement with this groundbreaking research is planned through a live conversation between Gallimore and Hoffman on June 13, 2026, at the Lighthouse, a creative venue located in the historic Venice Beach Post Office. This event will be recorded and made widely accessible via YouTube, signaling the teams’ commitment to transparency and broader dissemination of their scientific insights.

Noonautics operates as a 501(c)(3) non-profit research organization dedicated to public-facing investigations into the mind’s structure and the nuances of non-ordinary experience. Its director, Dr. Andrew R. Gallimore, is renowned for his contributions to DMT research, including the co-invention of the DMT extended-state pharmacokinetic framework known as DMTx. His base at the Okinawa Institute of Science & Technology positions him at the nexus of cutting-edge neuropharmacological research.

The Trace Institute similarly functions as a non-profit entity, committed to developing a mathematically grounded science of reality centered on conscious observers. Its founder, Donald D. Hoffman, is known for foundational theories such as the interface theory of perception, conscious agent theory, and trace logic, all contributing to an observer-centric model of nature that challenges conventional physicalist assumptions.

The research preprint, entitled “Traces of the Other – Are DMT Entities Real? DMT Phenomenology in the Framework of Conscious Realism,” authored by Gallimore, Hoffman, and Hermansson, is available on PsyArXiv. This work comprehensively discusses the phenomenological intricacies of DMT-induced experiences in the context of conscious realism, constructing a novel interpretative lens grounded in both qualitative and quantitative dimensions.

Through this collaboration, the traditionally fringe subject of psychedelic experience is being subjected to the rigor of formal scientific scrutiny, promising to bring about a paradigm shift not only in psychedelic research but in consciousness studies broadly. By leveraging mathematical models, extended experiential protocols, and interdisciplinary dialogue, these researchers are charting an unprecedented course toward decoding the perennial mysteries of the human mind and its interface with the fabric of reality.

The potential repercussions of this research extend beyond academia, potentially informing new approaches in mental health therapies, cognitive enhancement technologies, and our conceptual frameworks concerning the mind-world relationship. As science increasingly embraces altered states of consciousness as legitimate domains of inquiry, initiatives like this will likely catalyze innovative methodologies and theoretical breakthroughs.

As humanity ventures deeper into the exploration of subjective experience, this pioneering work underscores the vital importance of bridging first-person phenomenology with third-person scientific analysis. The collaboration between Noonautics and the Trace Institute embodies this integrative vision, pioneering a frontier that not only seeks to map altered states but also to redefine our understanding of consciousness and reality itself.

Subject of Research: People
Article Title: Mathematical Modeling of the Human Psychedelic Experience
News Publication Date: Not specified
Web References: http://dx.doi.org/10.31234/osf.io/8qvgy_v2
References: Gallimore, A.R., Hoffman, D.D., Hermansson, N., “Traces of the Other – Are DMT Entities Real? DMT Phenomenology in the Framework of Conscious Realism,” PsyArXiv, DOI: 10.31234/osf.io/8qvgy_v2
Image Credits: Not specified

Keywords: Neuroscience, Mathematics, Modeling, Neuropsychology, Pharmaceuticals

The original research embraced a holistic perspective by conducting three separate yet interrelated systematic reviews and meta-analyses, each examining distinct facets of psychedelic substances. The pharmacological review extensively cataloged and analyzed the biochemical interactions of classic psychedelics—compounds primarily acting on serotonergic systems such as the 5-HT2A receptor. This review meticulously compiled data across numerous studies, providing high-resolution insight into receptor binding affinities, dose-response relationships, and downstream neurochemical cascades. Such biochemical granularity is crucial for delineating the therapeutic windows and safety profiles of these agents, which have shown promise in treating mental health disorders including depression, anxiety, and PTSD.

Simultaneously, the neuroimaging meta-analysis harnessed neurofunctional and structural brain data derived from functional Magnetic Resonance Imaging (fMRI), Positron Emission Tomography (PET), and Magnetoencephalography (MEG). This layer of investigation revealed convergent patterns of brain activity modulation induced by psychedelics, such as enhanced connectivity within the default mode network (DMN), and decreased modular segregation across cortical regions. These neuroplasticity-related changes correlate strongly with altered states of consciousness and cognitive flexibility, offering mechanistic explanations for the reported subjective effects and long-term psychological benefits of psychedelic therapy. The synthesis of these imaging data across numerous cohorts marks a pivotal step in validating neurobiological models of psychedelic action.

Complementing these objective measures, the phenomenological review synthesized qualitative data from psychometric assessments, narrative reports, and validated consciousness scales. This branch of research illuminates the intricate landscape of subjective experience—including ego dissolution, mystical-type experiences, emotional breakthroughs, and perceptual distortions—that are central to both the cultural significance and clinical efficacy of psychedelics. By systematically categorizing and quantifying these lived experiences, the review bridges the gap between measurable brain alterations and their psychological manifestations, creating a cohesive framework by which subjective phenomenology can be scientifically scrutinized and therapeutically harnessed.

The integrative nature of this triadic research approach propels the understanding of psychedelics beyond isolated analyses into a multi-dimensional model that synergizes biochemical, neurophysiological, and psychological data. The correction published in Translational Psychiatry ensures that this model remains robust and reproducible, addressing previous data inconsistencies and methodological refinements that enhance the interpretability of results. The amended results reinforce the notion that psychedelics act as modulators of brain network dynamics and personal consciousness, with therapeutic implications that extend far beyond symptom alleviation to potential catalysis of enduring psychological transformation.

This revised synthesis underscores the importance of dosage calibration and individual variability, revealing that the interplay between neuropharmacological potency and experiential context is more nuanced than previously thought. Such insights stress personalized approaches in both research design and clinical protocols, advocating for adaptive titrations aligned with patient-specific neural and psychological profiles. The neurobiological markers identified through imaging studies could serve as predictive biomarkers for therapeutic responsiveness, streamlining patient selection and optimizing treatment outcomes.

Furthermore, the corrected data emphasizes the critical role of serotonin 2A receptor agonism as a nexus in initiating the psychedelic state, while also suggesting contributions from additional receptor systems and neuromodulatory circuits. This broader pharmacological perspective widens the scope for the development of next-generation psychedelics with tailored receptor profiles optimized for efficacy and tolerability. Insights garnered from molecular interaction studies may open pathways for the design of compounds that selectively engage cognitive and emotional circuits relevant to distinct psychiatric conditions.

One of the most compelling advancements lies in the elucidation of how psychedelics facilitate large-scale brain network reorganization. The reconfiguration of connectivity patterns observed in neuroimaging meta-analyses aligns with theoretical models proposing that psychedelics act as neurodynamic modulators. These substances appear to transiently reduce hierarchical constraints within cortical networks, thus enriching information flow and cognitive flexibility. By temporarily suspending entrenched neural and psychological patterns, psychedelics may provide windows of opportunity for therapeutic reprogramming of maladaptive mental states.

The phenomenological data corrected and refined within this framework present critical considerations for therapeutic applications, highlighting that the quality and integration of the psychedelic experience substantially influence clinical outcomes. Mystical-type experiences, characterized by feelings of unity and transcendence, consistently correlate with positive treatment effects, suggesting that subjective experience is not merely epiphenomenal but central to psychedelic efficacy. These findings underscore the necessity for skilled psychological guidance and supportive set and setting to maximize beneficial outcomes while minimizing risks.

Moreover, the meta-analytic approach strengthens the evidence base by mitigating sample heterogeneity and publication bias, thereby enhancing the generalizability and reliability of findings across diverse populations and psychedelic compounds. The inclusion of multiple psychedelic agents—such as psilocybin, LSD, DMT, and mescaline—within the analyzed datasets allows for comparative evaluations of their neurobiological and phenomenological profiles, clearly delineating commonalities and distinctive traits that can inform therapeutic stratification.

The correction further calls attention to the dynamic interplay between neuroplasticity and psychological insight engendered by psychedelics. Emerging evidence suggests that these substances potentiate synaptic plasticity and neurogenesis, mediated by key signaling pathways including brain-derived neurotrophic factor (BDNF). Such molecular mechanisms might explain the sustained psychological benefits observed long after the acute effects dissipate, supporting models of psychedelics as catalysts for profound neurocognitive remodeling.

Importantly, the updated integrative review emphasizes the translational potential of these findings, advocating for their incorporation into clinical trial design and psychiatric practice. By clarifying the multi-level mechanisms underpinning psychedelic action, the study provides a scientifically rigorous foundation to support regulatory frameworks and therapeutic protocols. This harmonized understanding could accelerate drug development pipelines and guide evidence-based policy-making, ultimately facilitating wider access to psychedelics in mental health care.

In the wake of these pivotal corrections, the scientific community is poised to refine experimental paradigms, embracing multi-modal methodologies that span molecular neuroscience, systems biology, and phenomenological inquiry. Future research will likely expand upon this groundwork, employing cutting-edge techniques such as high-resolution connectomics, real-time neurofeedback, and computational modeling to deepen mechanistic insights. Such endeavors promise to unravel the intricate tapestry of psychedelic effects with unprecedented precision.

In sum, this correction to the integrated series of systematic reviews and meta-analyses marks a landmark moment in psychedelic science. It not only rectifies previous ambiguities but also elevates a synergistic understanding that encompasses receptor pharmacodynamics, network-level brain modulation, and complex subjective experience. As the field progresses, these insights will be foundational to the responsible and effective clinical deployment of psychedelics, heralding an era of transformative mental health interventions grounded in rigorous, multi-disciplinary science.

Subject of Research: A synergistic, multi-level understanding of psychedelics, integrating pharmacology, neuroimaging, and phenomenology through systematic reviews and meta-analyses.

Article Title: Correction: Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.

Article References:
Shinozuka, K., Jerotic, K., Mediano, P. et al. Correction: Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology. Transl Psychiatry 15, 470 (2025). https://doi.org/10.1038/s41398-025-03731-7

Image Credits: AI Generated